Navigation Links
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma patients, 16 years or older in a randomized, multicenter, double-blind Phase II study of a trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  

In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  The addition of chemotherapy to surgical resection has not shown to improve outcome in adult patients with sarcoma. Thus, in the majority of cases, the current standard of care following treatment of metastatic disease and the achievement of disease-free status is expectant management.

The vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.  The vaccine is intended to instruct the patient's immune system to make antibodies against the three ganglioside ant
'/>"/>

SOURCE MabVax Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... Dallas, TX (PRWEB) , ... July 27, 2015 , ... ... remainder of 2015. , The center invites all those prospective joint-replacement patients, along ... Monday and Thursday of each month, with Monday classes (Aug 6, Sept 8 [Tue ...
(Date:7/27/2015)... ... 27, 2015 , ... Send Word Now, the ... collaboration, announced today the latest software release for its award-winning alerting service, ... , This software release gives the widely used online application a fresh look ...
(Date:7/27/2015)... Houston, TX (PRWEB) , ... July 27, 2015 , ... ... million in actual and punitive damages against Canadian stock promoter Robert Kubbernus based on ... down by a twelve-person jury and accepted by the court in Cause No. 2010-09675; ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... ... entitled "Applying Data To Reduce Hospital Readmissions." , The Centers for Medicare and ... facility-level data used as part of their penalty calculation. Known as the QualityNet ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2
... Canadian Cancer Society has recommended that citizens of all ages should ... and that elderly people// should take Vitamin D supplements. ... 'Oh good, I can stay out in the sun all day,' ... little sun goes a long way. You don't need to get ...
... month study conducted by the rheumotologists in the University ... in the form of Adkins-type diet for weight loss, ... contrary to the earlier findings conducted in animal studies. ... the online issue of the journal Osteoporosis International. Low ...
... doctors here sucessfully removed a 'minute spring' which had got ... // ,Dr Palaniappan of Apollo Hospital here, who ... told PTI here that Muniraj was suffering from a wheezing ... one-and-a-half months., ,After trying different treatments, the boy's father ...
... human-to-human transmission of the deadly bird flu virus among members ... agency has sought to assure the public that potentially dangerous ... however maintained that human contagion cannot be ruled out in ... ,So far there has been no evidence that efficient human-to-human ...
... has been announced states that all the state schools are to ... This is part of their drive against obesity. , ... milk to pupils aged 3 to 18. The ruling also applies ... and to cartons sold in vending machines. ,This ban ...
... today took out a rally here to oppose the ... OBC in higher educational institutions. // ... and engineering colleges today took out a rally and ... and other important places of the city to convey ...
Cached Medicine News:Health News:Good News For The Obese People 2Health News:All State Run Schools Are To Ban Whole Milk To Children 2Health News:All State Run Schools Are To Ban Whole Milk To Children 3
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: